The role of adenosinergic pathway in human autoimmune diseases by unknown
REVIEW
The role of adenosinergic pathway in human autoimmune diseases
Ke Dong1 • Zhao-wei Gao1 • Hui-zhong Zhang1
Published online: 24 September 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Autoimmune diseases are characterized by the
abnormal immune response against self-tissue, which are
caused by the failure of nature immune homeostasis. Nat-
ure immune homeostasis represents the normal state of
appropriate immune response to nonself-antigen and
unresponsiveness to self-antigens. In normal situation,
immune homeostasis is regulated by immunosuppressive
signal and immunostimulating signal together. Accumu-
lating data have demonstrated that the adenosinergic
pathway played key roles in immune suppression and
shield body from an excessive inflammatory response. The
deficiency of adenosinergic pathway results in the imbal-
ance between the pro- and anti-inflammatory activities.
Thus, researchers pay much attention to the role of
adenosinergic pathway in autoimmune diseases develop-
ment. To date, accumulating data have suggested an
important role of adenosinergic pathway-related molecules
(i.e., CD39, CD73, ADA, adenosine receptors, etc.) in
many types of human autoimmune diseases. More impor-
tantly, these findings have presented potential value of
adenosinergic pathway analysis to be used for autoimmune
diseases diagnosis, monitoring and treatment. In this
review, we will provide a comprehensive description of the
role of adenosinergic pathway in human autoimmune
diseases.
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Introduction
Autoimmune diseases are caused by the deficiency or
losing of nature immune tolerance. Under certain circum-
stance, immune system attacks the self-antigens, following
with excessive immune response, which leads to autoim-
mune diseases to happen [1, 2]. The autoimmune diseases
may be restricted to certain tissues, organs or the whole
body. The frequent autoimmune diseases include RA
(rheumatoid arthritis), SLE (systemic lupus erythemato-
sus), MS (multiple sclerosis), T1DM (Type I diabetes
mellitus), JIA (Juvenile idiopathic arthritis), AIH (au-
toimmune hepatitis), etc. The basic function of human
immune system is distinguishing antigens and then elimi-
nates the nonself-antigens and protects the body from
infection, tumor, etc. In normal situation, there is ‘‘alarm’’
signal which generates various cellular responses that aim
to prevent excessive inflammatory response and restore the
immune homeostasis. Several lines of evidence have
demonstrated that adenosine behaves as the ‘‘alarm’’ signal
in vivo. Adenosine activates adenosine receptors on target
cells, generates multiple cellular responses and then sup-
presses the immune response [3, 4]. Thus, deficiency of
adenosinergic pathway may result in the disorder of
immune response. Recent years, researchers pay much
attention to the role of adenosinergic pathway in autoim-
mune disease development. This present review will pro-
vide a comprehensive description of the role of
adenosinergic pathway in human autoimmune diseases.
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Adenosinergic pathway regulates immune
imbalance during autoimmune diseases
progression
Immune imbalance in autoimmune diseases
Autoimmune diseases arise from an abnormal immune
response against self-tissues and cells and lead to the
injury. In normal situation, the immune response is regu-
lated by immunosuppressive signal and immunostimulating
signal together. A fine balance between immunosuppres-
sive and immunostimulating signals is important for
maintaining the homeostasis of immune system. Accumu-
lating data have shown that disturbed balance of immune
system was involved in development of autoimmune dis-
eases. The main T cell subsets which are pivotal for this T
cell balance consist of T helper (Th) cells and regulatory T
(Treg) cells, and moreover, Th cells are defined as Th1,
Th2 and Th17 subtypes characterized by differential
expression of certain cytokines. In SLE, increasing evi-
dences have demonstrated that the disrupted balance
between Th cells and Treg cells contributed to the disease
development [5–9]. Deficiencies of Treg cells, either
quantitative or functional, were found in active lupus
patients, while the number of Th17 cells, as well as Th17-
related cytokines, was found increased in SLE patients
[10–12]. Studies have reported higher concentration of IL-
17 in the serum and synovial fluid of RA patients compared
to controls [13, 14]. IL-17 is the main cytokine secreted by
Th17 cells, which indicated that the number and/or activity
of Th17 cells was increased in RA patients, while studies
showed that the percentage of circulating Treg cells in RA
patients was reduced compared to healthy controls [15].
Similarly, imbalance of Th cells and Treg cells has been
noted in T1DM [16]. The imbalance is manifested by
expansion of Th17 cells which is concomitant with
decreased number or function of Treg cells. Taken toge-
ther, above data demonstrated that the disrupted home-
ostasis of immune system played a critical role in the
autoimmune diseases development.
Adenosine signaling pathway
Adenosine is an important immunosuppressive signal in the
internal environment, which can shield cells and tissues
from an excessive inflammatory response and immune-
mediated damage [4, 17]. Extracellular adenosine con-
centration is determined by a complex ectoenzyme mech-
anism and uptake system [3, 18]. The generation of
adenosine in the internal environment is regulated by a
cascade of enzyme (Fig. 1). Adenosine is generated from
degradation of ATP which is catalyzed by the enzyme
cascade as follows: ATP/ADP breakdown into AMP by
CD39 (ecto-nucleoside triphosphate diphosphohydrolase 1,
E-NTPDase1), AMP breakdown into adenosine by CD73
(ecto-50-nucleotidase, NT5E). Adenosine can be catalyzed
into inosine by ADA (adenosine deaminase) and its
cofactor CD26 (dipeptidyl peptidase 4). Uptake system,
which includes ENTs (equilibrative nucleoside trans-
porters) and CNTs (concentrative nucleoside transports),
shunt extracellular adenosine into the intracellular space,
thereby regulating the concentration of extracellular ade-
nosine and terminating adenosine receptor signaling.
Adenosine activates its G-protein-coupled cell-surface
receptors on target cells, which generate various cellular
responses that aim to restore immune homeostasis. Up to
date, four adenosine receptors have been identified: A1R,
A2AR, A2BR and A3R. A1R, A2AR and A2BR are con-
served and highly homologous (80–95 %), whereas A3R
varies substantially among different species [19]. Adeno-
sine receptor signaling depends on the level of extracellular
adenosine. Accumulating data have demonstrated that
adenosine behave as an immunosuppressive signal via
activating its receptors.
Adenosine pathway mediate immune suppression
Accumulated data have shown that adenosinergic pathway-
mediated immune suppression and played an important
role in maintaining the homeostasis of immune system
(Fig. 1). The regulatory T cells (Treg cells), also known as
suppressor T cells, are a subpopulation of T cells which
modulate the immune response and maintain immunolog-
ical tolerance. Treg cells generally suppress immune
response by suppressing the proliferation and function of
effect T cells. Romio et al. showed that the suppressive
function of Treg cells was dependent on the CD73
expression on Treg cells surface. They found that CD73-
positive Treg cells strongly inhibited proliferation of
CD4?CD25--effective T cells in co-culture experiments,
while there was no significant inhibited function when
experiments were performed with Treg cells lacking CD73
[20].
Smyth et al. [21] found that Treg cells suppressed
effective T cells via the production of secreted membrane
vesicles, such as exosomes. Moreover, their results showed
that CD73 was expressed on Treg-derived exosomes and
contributed to Treg cell’s suppressive activity through the
production of adenosine. The exosomes derived from
CD73-positive Treg cells can significantly inhibit CD4?-
CD25- effect T cells proliferation, while the exosomes
derived from a CD73-negative Treg cells lack the sup-
pressive capacity. Notably, the suppressive capacity of
exosomes derived from CD73-positive Treg cell is in a
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dose-dependent manner. Romio et al. reported that CD73
regulated suppressive function of Treg cells via activating
A2AR which are expressed on target cells. The prolifera-
tion of CD4?CD25- effect T cells was significantly
inhibited by A2AR-specific agonist—CGS21680. And
moreover, the expression level of inflammation factors
(TNF-a, IL-2, IFN-c, IL-13, IL-4, IL-1a, IL-1b) was also
significantly inhibited by CGS21680 treatment [20]. Ohta
et al. [22] found that A2AR agonist CGS21680 promoted
Treg cells proliferation, while A2AR antagonist
ZM241385 inhibited Treg cells proliferation. These data
suggested that the activity of adenosine pathway was
necessary for suppressive activation of Treg cells. More-
over, adenosine has been shown to regulate the differen-
tiation of macrophage through A2A and A2B receptors.
Adenosine increases alternative-macrophage activation,
which includes various anti-inflammatory macrophage
phenotypes, by inhibiting M1-macrophage activation and
promoting M2-macrophage polarization [23]. Adenosine
can also regulate dendritic cell differentiation and function.
The stimulation of A2AR can decrease MHC-II expression
and deregulate the antigen-presentation activation of den-
dritic cells, which can furthermore reduce immune
response [24]. Taken together, these results demonstrated
that adenosine pathway played a key role in the suppres-
sion of inflammatory response.
Adenosine pathway changes in human
autoimmune diseases
Development of autoimmune diseases is associated with
the deficiency of immune-suppressive signal, in which the
adenosine has been demonstrated to play an important role.
Therefore, researchers pay attention to study the role of
adenosine pathway in autoimmune diseases. Up to date,
accumulating data have shown the role of adenosinergic
pathway-associated molecules in several types of autoim-
mune diseases (Table 1).
Rheumatoid arthritis
Rheumatoid arthritis is a chronic autoimmune disease with
joint destruction and severe morbidity. It is characterized
by synovial infiltration of inflammatory cells secreting pro-
inflammatory cytokines. By using collagen-induced
arthritis (CIA) mouse models, which is a commonly used
mouse model for RA study, Chrobak et al. found that
Fig. 1 Adenosine pathway
mediates immune suppression.
A scheme illustrates the
generation of adenosine and the
adenosine receptor signaling
pathway that mediates immune
suppression. Adenosine is
generated from degradation of
ATP by CD39 & CD73. The
adenosine pathway mediates the
immune suppression by
regulating the function of
immune cells, such as T cells,
dendritic cells and macrophages
Immunol Res (2016) 64:1133–1141 1135
123
CD73-deficient mice were significantly more susceptible to
CIA than wild-type (WT) mice. CD73 deficiency resulted
in an increased production of pro-inflammatory cytokines
(IL-1b, IFN-c, TNF-a, IL-6) in joint and increased joint
destruction. In summary, their results demonstrated that
CD73 played a protective role in rheumatoid arthritis. In
addition, by using A2AR-specific agonist—CGS21680—
Chrobak also found that stimulation of A2AR in CD73-
deficient mice resulted in arthritis incidence similar to
wild-type mice. These data were supported by other inde-
pendent studies which showed a beneficial effect of
CGS21680 on CIA severity in mice models [25].
Methotrexate (MTX) is the standard first-line therapy of
rheumatoid arthritis. However, a significant percentage of
rheumatoid arthritis patients are resistant to MTX treat-
ment. Peres et al. [26] found that MTX unresponsiveness in
rheumatoid arthritis patients was associated with low
expression of CD39 on Treg cells and the deceased sup-
pressive activity of Treg cells through reduced adenosine
production. These data suggested that low expression of
CD39 on Treg cells could be a biomarker for identifying
MTX-resistance rheumatoid arthritis patients. Vinapamula
et al. [27] have found that serum ADA levels were higher
in rheumatoid arthritis patients (N = 46) compared to
controls (N = 46), which suggested that serum ADA could
be as inflammatory marker for rheumatoid arthritis
patients. However, we recently investigated the serum
ADA levels in 60 rheumatoid arthritis patients and 60
healthy controls (age and sex matched, Chinese people),
and our results showed that there was no significant dif-
ference of serum ADA in RA patients compared to controls
(unpublished data). Up to now, ADA is not a biomarker for
RA clinical diagnosis. Thus, further studies in larger
number of RA patients are needed to evaluate whether
serum ADA can be used as a biomarker for RA patients.
Taken together, above results supported that adenosinergic
pathway was involved in RA development, diagnosis and
therapy.
Systemic lupus erythematosus
Systemic lupus erythematosus is a systemic autoimmune
disease with unknown etiology, which affects almost all the
organs and tissues. Increasing evidences have suggested
that the disturbed T cell homeostasis plays a critical role in
the development of SLE. Dolff et al. [28] have reported
Table 1 Function of adenosine pathway in various autoimmune diseases
AID type Conclusion References
Rheumatoid arthritis Methotrexate unresponsiveness in RA is associated with low expression of CD39 on Treg cells
CD73-deficient mice are significantly more susceptible to collagen-induced arthritis, while this increased
susceptibility of CD73-deficient mice to CIA is reversed by A2AR activation






CD39 and CD73 expression levels in Treg cells were decreased in active SLE patients as compared to
healthy controls and inactive SLE patients






Diminished A1R expression in pancreatic alpha-cells contributes to the pathology of type 1 diabetes
A3R activation markedly reduced Beta-TC6 cells proliferation, while this effect was partially blocked by
the A3 antagonist





Multiple sclerosis CD73-deficient mice are more resistant to experiment autoimmune encephalomyelitis. A2AR antagonist
protected WT mice from EAE induction through blockage of A2AR signaling
[38]
Myasthenia gravis Serum ADA activity of MG patients is significantly higher as compared to normal control





In AIH, CD39-positive Tregs are decreased in number and fail to adequately hydrolyze proinflammatory
nucleotides and do not efficiently suppress IL-17 production by effector T cells






Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and
higher disease severity in juvenile idiopathic arthritis
[49]
Autoimmune uveitis A3R agonist can ameliorate the pathological manifestations of the EAU
A2B agonist greatly enhanced the development of EAU
[51]
[52]
1136 Immunol Res (2016) 64:1133–1141
123
that imbalance of Treg and Th cells contributes to the
pathogenesis of SLE. Valencia found that the Treg cells
number and immunosuppressive activation were signifi-
cantly decreased in the peripheral blood of patients with
active SLE as compared to healthy controls and patients
with inactive SLE [11]. Li et al. [29, 30] found that the
CD39 and CD73 expressions in Treg cells were decreased
in active SLE patients as compared to healthy controls and
inactive SLE patients. Notably, the adenosine-generatin-
genzymes expression levels (CD39, CD73) were found to
be decreased, while the activity of adenosine degradation
enzyme—ADA—was increased in SLE patients. Saghiri
et al. [31] showed that total ADA activity and ADA2
activity (one of ADA isoenzymes) were increased in serum
of SLE patients and suggested that ADA and its isoen-
zymes analysis in serum could be used as a useful and
noninvasive marker in evaluation of SLE active phase and
disease severity. And moreover, the adenosine receptor has
been found to be involved in the progression of SLE. By
using MRL/lpr mouse model, which shares many charac-
teristics of human SLE, Zhang et al. found that CGS21680
treatment resulted in significant decrease in albuminuria,
hematuria and renal immune complex deposition as well as
improvement in renal histology. This result demonstrated
that A2AR stimulation ameliorated the severity of nephritis
and renal vasculitis in MRL/lpr mouse model and, more-
over, suggested that A2AR could be considered as a
potential therapeutic target for human lupus nephritis [32].
Taken together, above studies demonstrated that adenosine
signaling pathway played an important role during SLE
progression.
Type 1 diabetes
Type 1 diabetes mellitus is an organ-specific autoimmune
disease caused by immune-mediated destruction of the
insulin-producing pancreatic b cells. Accumulating evi-
dences highlight a critical role for the adenosine signaling
pathway in the pathophysiology of T1DM [33].
Several studies showed that adenosine could regulate
pancreatic b cells homeostasis by controlling its prolifer-
ation and regeneration. As we know, pancreatic b cells are
biosensors that detect fluctuations of blood glucose levels
and release appropriate amounts of insulin when required.
In one of these studies, performed in a zebrafish model,
Andersson found that adenosine agonist NECA (50-N-
ethylcarboxamidoadenosine) potently increased the regen-
eration of b cells by promoting their proliferation, and
NECA’s effect on b cells proliferation was shown to be
mediated by one of zebrafish orthologs of the A2A receptor
(called A2aa) [34]. And furthermore, the proliferative and
lowering effect of NECA was confirmed in diabetic mice
models, suggesting an evolutionarily conserved role for
adenosine signaling pathway in b cells proliferation. In
addition, another study showed that NECA strongly sup-
pressed expression of the proinflammatory cytokines TNF-
a, MIP-1a, IL-12, and IFN-c in pancreata, splenic cells and
T helper 1 lymphocytes, indicating that the benefit of
NECA in diabetes therapy was due to immunomodulation
[35]. By using mouse pancreatic b-cell line Beta-TC6,
Ohtani found that A3 receptor agonist (Cl-IB-MECA)
markedly reduced Beta-TC6 cells proliferation, while this
effect of A3 agonist was partially blocked by the A3
antagonist [36]. These results suggested that the A3
receptor was involved in modulation of the survival of
pancreatic b cells. Moreover, Ohtani also found that ade-
nosine augmented insulin secretion by mouse islets in the
presence of either normal or high concentration of glucose
via A2A receptor, while this stimulatory effect could be
blocked by the treatment with A2A receptor antagonist-
SCH58261. Above results suggested that adenosine
receptors played an important role in diabetes development
and could be potential target for T1DM therapy.
Besides adenosine receptors, CD73, which is a key
enzyme for adenosine generation, has also been found to be
involved in T1DM development. Tai et al. [37] have
showed that TLR9 deficiency in nonobese diabetic mice
could significantly protect from T1DM development via
up-regulating CD73 expression. This finding indicated that
CD73 played an important role in diabetes protection, and
might be a therapeutic target for T1DM in humans.
Multiple sclerosis
Multiple sclerosis is a chronic inflammatory autoimmune
disease of the central nervous system (CNS), due to an
immune reaction against myelin proteins. The etiology of
MS is still unclear. Increasing evidences have suggested
that adenosinergic system may be an important factor in
MS pathophysiology. Mills et al. demonstrated that CD73-
deficient mice were more resistant to experiment autoim-
mune encephalomyelitis (EAE, which is the classical ani-
mal model of MS). In addition, it was observed that the
infiltration of lymphocytes into CNS in CD73-deficient
mice was fewer than that in WT mice. And moreover, they
found that SCH58261 protected WT mice from EAE
induction through blockage of A2AR signaling. Lympho-
cyte infiltration into the CNS was diminished in mice
treated with A2AR antagonist or through A2AR knock-
down [38]. These findings indicate that the activation of
CD73 and A2AR is the promotive factors during EAE
development via facilitating lymphocyte migration into
CNS. Similarly, A2BR expression is increased in MS
patients and EAE mice models, and A2BR-specific
antagonists (CVT6883 and MRS-1754) can remit of EAE
disease and protect the CNS from immune damage [39].
Immunol Res (2016) 64:1133–1141 1137
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However, for the other adenosine receptor-A1R, several
lines of evidence have showed that A1R may have the
protective function in EAE. Firstly, the expression of A1R
is reduced in MS patients [40]. Secondly, A1R-deficient
mice show more severe forms of progressive and relapsing
EAE compared to WT mice [41]. Thirdly, activation of
A1R reduces inflammatory response in the CNS [40].
These results demonstrate the different role of adenosin-
ergic pathway-related molecules in MS development.
Myasthenia gravis
Myasthenia gravis (MG) is a T cell-dependent autoimmune
disease characterized by excessive muscle weakness and
fatigue. The experimental autoimmune myasthenia gravis
(EAMG) rat is a classic animal model of MG, which can be
induced by immunization of rats with the acetylcholine
receptor (AChR) R97–116 peptide [42]. As early as in
1990, Chiba et al. [43] reported that the serum ADA
activity of MG patients (n = 30) was significantly higher
as compared to that in normal control (n = 150). Oliveira’s
data showed that serum ADA activity in EMAG animals
was significantly higher than that in both control and native
animals [44]. We recently investigated the serum ADA
activity of MG patients (n = 50); however, our results
revealed that there was no significant difference between
MG patients and healthy controls (unpublished data). Thus,
the serum ADA activity should be investigated in more
MG patients. Li et al. [45] reported a reduction of A2AR
expression in both T cells and B cells residing in spleen and
lymph nodes following EAMG induction. A2AR stimula-
tion inhibited anti-AChR antibody production and prolif-
eration of AChR-specific lymphocytes in vitro.
Furthermore, preventive treatment of EAMG with
CGS21680 was effective in down-modulating disease
manifestations and therapeutic treatment partly attenuated
the severity of established EAMG. In a recent study, Li
et al. [46] evaluated adenosine receptor expression in
EAMG rats and found that lymphocyte A1R and A2AR
expression levels were decreased, while there was no sig-
nificant change in A2BR and A3R expressions. Thus, Li
et al’s [44] data demonstrated the critical role of A2AR
during MG progression and presented the potential
opportunities to develop A2AR targeting therapeutic
approach. Recently, Oliveira found that CD4?CD25?-
FoxP3? regulatory T cells of EAMG expressed lower
amount of CD73 as compared to controls. The reduction of
CD73 expression and adenosine receptors in EMAG rats
strongly suggests that the adenosine signaling pathway may
be the dysfunction during MG progression. Thus, stimu-
lation of CD73 or A2AR may have therapeutic potential in
MG.
Autoimmune hepatitis
Autoimmune hepatitis is an inflammatory disease of the
liver, characterized by female preponderance, interface
hepatitis on histology and autoantibody positivity.
Numerical and functional defects of Treg cells are likely to
play a permissive pathogenic role in AIH. Several lines of
evidence have demonstrated the role of adenosine pathway
in AIH. Grant et al. [47] found that the number of CD39?
Treg cells was decreased in AIH, which resulted in failure
to efficiently suppress IL-17 production by effector T cells.
In a recent study, Liberal et al. [48] reported that the
expression of CD39 and A2AR was significantly dimin-
ished in Th17 cells from autoimmune liver disease patients,
and these decreases were associated with impaired gener-
ation of immunosuppressive adenosine and defective reg-
ulatory properties. These data indicated that adenosinergic
pathway involved in AIH development by impairing the
immune regulatory function of Treg and Th cells.
Other autoimmune diseases
Juvenile idiopathic arthritis is a chronic autoimmune
rheumatic disease of childhood with unknown etiology,
characterized by swelling of the joints and thickening of
synovial lining. Botta et al. [49] found that the expression
level of CD73 on synovial fluid mononuclear cells
(SFMCs) from JIA patients was lower than that in
peripheral blood mononuclear cells (PBMCs) from both
JIA patients and healthy controls. And moreover, low
expression of CD73 on T and B cells in inflamed site is
correlated with the clinical severity of JIA patients. This
finding suggested that the decreased CD73 expression in
SFMCs would lead to a decreased potential for anti-in-
flammatory activity and then, the deterioration of disease.
Uveitis is an inflammation involving the middle layer of
the eye with a high risk of blindness, which can be caused
by autoimmune disorder and infection. Experiment
autoimmune uveitis (EAU) is a mouse model of endoge-
nous uveitis in humans. In recent years, several studies
reported the role of adenosinergic pathway in uveitis by
using EAU models. Liang et al. [50] found that cd T cells
expressed different amounts of CD73 during the different
stages of EAU. However, the function of CD73 expression
in uveitis has not been well demonstrated. Bar-Yehuda
et al. found that treatment with the highly selective A3R
agonist—CF101—can ameliorate the pathological mani-
festations of the EAU. This result supported further
exploration of CF101 for the uveitis therapy [51]. How-
ever, unlike the A3R agonist, Chen et al. [52] showed that
selective A2B agonist greatly enhanced the development of
EAU, whereas treatment with A2B antagonist significantly
ameliorated severity of EAU. Taken together, these data
1138 Immunol Res (2016) 64:1133–1141
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suggested the different effect of the adenosine receptor
subtypes involved in uveitis development.
Conclusion
Autoimmune diseases are caused by disruption of natural
immune homeostasis and failure of immune tolerance.
Under natural circumstance, the immunosuppressive signal
and stimulative signal inter-restrict with each other and
maintain the immune homeostasis together. While, the
immunosuppressive effects of adenosine present the
potential roles of adenosinergic pathway in the develop-
ment of autoimmune diseases. Indeed, in recent years,
increasing data support that adenosinergic pathway plays
an important role in various types of autoimmune diseases,
and moreover, this discovery shed new light on the diag-
nosis, monitoring and therapy of certain autoimmune dis-
eases. For diagnosis and monitoring, the increased serum
ADA activity in RA and SLE patients present the potential
value of serum ADA level that served as a biomarker. For
therapy, the connection between low CD39 expression in
RA patients and methotrexate unresponsiveness suggests
that CD39 expression analysis can be used to identify
methotrexate-responsive RA patients. And moreover, some
agonist/antagonist of adenosine receptors has displayed
favorable curative effect in animal models. Notably, The
CF101, which is the specific agonist of A3R, is currently
undergoing testing in clinical trials for the treatment of
rheumatoid arthritis patients [56, 57]. Although other
agonist of adenosine receptors has not been translated into
clinical patients, the results in animal models have revealed
that adenosine receptors target therapy may be an alter-
native and realistic therapeutic approach for autoimmune
diseases in the future. Thus, future studies aiming at
translating adenosinergic pathway target therapy into
clinical patients can be expected. Notably, the cardiovas-
cular side effects of a A2AR agonist—GW328267X—have
been found in clinical trials of chronic obstructive pul-
monary disease treatment [3]. Thus, because of multiple
effects of adenosinergic signaling on immune system,
although adverse events has not yet been observed in ani-
mal models of autoimmune diseases, the potential toxic
risk of adenosinergic pathway target therapy cannot be
ignored and must be argued carefully before translating
into autoimmune disease patients. Up to now the total
studies focused on the role of adenosinergic pathway in
human autoimmune diseases are still few, and more studies
are required to completely evaluate the adenosinergic
pathway and its contribution in autoimmune disease
development.
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